Joining us now is Dr. Francisco Contreras, and we have talked before in the past,

and he does an integrative approach to cancer treatment.

And he wanted to talk specifically about some of the antiparcytics that people are talking about,

ivermectin, fimbendazol, and another one which I've, which is new to me.

We're going to talk to him about that.

What the safety profile is on that and what kind of success rate they've seen with that.

His organization is a hospital in Tijuana, Mexico, and it is Oasisofhope.com.

Thank you for joining us, sir.

Thank you very much.

It's a pleasure and an honor.

Well, it is an honor to have you on, and as I was telling you before we started the interview,

this is something that's very important to me because I have seen both my father and my sister die

from the therapy

itself, the cancer treatment itself, and got to them before the cancer did. And so, and I know

I've had many friends that have gone through this as well. I was looking at the information

about your hospital, and we've talked once before. And, but what you have here is some differences between the rates of success on stage

four cancer versus the United States.

And on stage four cancer, you're anywhere from some of these are two times, the survival

rate, some of them three times of survival rate, one of them, 12 times the survival rate, some of them three times

of survival rate, one of them 12 times the survival rate of the United States for pancreatic

cancer, for example, 25% at Oasis of Hope versus the average across the U.S. of 2%.

Look at things like melanoma, it's three times. It's 75% chance as well as breast cancer,

...